Role of neutrophil‑lymphocyte ratio, platelet‑lymphocyte ratio, lymphocyte‑monocyte ratio and platelets in prognosis of patients with prostate cancer
- Authors:
- Joanna Huszno
- Zofia Kołosza
- Jolanta Mrochem-Kwarciak
- Ewa Telka
- Bożena Jochymek
- Leszek Miszczyk
View Affiliations
Affiliations: Radiotherapy Department, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, 44‑100 Gliwice, Poland, Department of Biostatistics and Bioinformatics, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, 44‑100 Gliwice, Poland, Analytics and Clinical Biochemistry Department, Maria Sklodowska‑Curie National Research Institute of Oncology Gliwice Branch, 44‑100 Gliwice, Poland
- Published online on: July 8, 2022 https://doi.org/10.3892/ol.2022.13425
-
Article Number:
305
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present analysis was to evaluate the platelet‑lymphocyte ratio (PLR), neutrophil‑lymphocyte ratio (NLR), lymphocyte‑monocyte ratio (LMR), platelets (PLT) and neutrophil level for their prognostic values in patients with prostate cancer who had been treated with radiotherapy. A retrospective analysis of 152 patients who were treated in the Radiotherapy Department at Maria Sklodowska‑Curie National Research Institute of Oncology (Gliwice, Poland) between January 2012 and December 2014 was performed. The prognostic value (overall survival; OS) of the pre‑treatment PLR, NLR, LMR, PLT, neutrophil level and other laboratory factors such as: leukocyte, lymphocyte, monocyte, hemoglobin, RBC, prostate‑specific antigen level (PSA), Gleason score, age, smoking and comorbid condition were assessed using univariate analysis. The cut‑off point was determined for NLR as ‘elevated’ at >4.66, LMR >3.26 and the PLR was considered ‘elevated’ at >89.6. Median follow‑up was 4.9 years. The 5 and 7‑year OS rates were 81.5 and 72.2%, respectively. In univariate analysis higher NLR (P=0.007), higher level of PLT (P=0.004), higher level of neutrophils (P=0.013), elevated level of leukocyte (P=0.043) and lymphocyte (P=0.043) were factors significantly associated with decreased OS. No difference was found for PLR (P=0.308) and LMR (P=0.109). The other factor associated with decreased OS were: higher Gleason score (>7; P=0.005), higher PSA level (>20 ng/dl; P=0.0001), smoking (P=0.003) and older age (>70 years; P=0.018). In multivariate analysis, NLR, LMR, leukocyte and RBC were independently associated with prognosis in patients with prostate cancer. Elevated pre‑treatment NLR [hazard ratio (HR)=10.83; P=0.001), LMR (HR=3.14; P=0.007) and higher leukocyte level (HR=3.14; P=0.007) were independently associated with increased mortality risk. Overall, pre‑treatment NLR, PLR, leukocyte and RBC levels were revealed to be independent prognostic factors.
View References
|
1
|
Rawla P: Epidemiology of prostate cancer.
World J Oncol. 10:63–89. 2019. View Article : Google Scholar
|
|
2
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar
|
|
3
|
Hutterer GC, Stoeckigt C, Stojakovic T,
Jesche J, Eberhard K, Pummer K, Zigeuner R and Pichler M: Low
preoperative lymphocyte-monocyte ratio (LMR) represents a
potentially poor prognostic factor in nonmetastatic clear cell
renal cell carcinoma. UrolOncol. 32:1041–1048. 2014.
|
|
4
|
Yin X, Xiao Y, Li F, Qi S, Yin Z and Gao
J: Prognostic role of Neutrophil-to-Lymphocyte Ratio in prostate
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 95:e25442016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nurden AT: Platelets, inflammation and
tissue regeneration. Thromb Haemost. 105 (Suppl 1):S13–S33. 2011.
View Article : Google Scholar
|
|
6
|
Goubran HA, Burnouf T, Radosevic M and
El-Ekiaby M: The platelet-cancer loop. Eur J Intern Med.
24:393–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Liu Y, Zhang N, Li X, Xin P, Bi J
and Kong C: Prognostic role of pretreatment platelet to lymphocyte
ratio in urologic cancer. Oncotarget. 8:70874–70882. 2017.
View Article : Google Scholar
|
|
8
|
Sciarra A, Gentilucci A, Salciccia S,
Pierella F, Del Bianco F, Gentile V, Silvestri I and Cattarino S:
Prognostic value of inflammation in prostate cancer progression and
response to therapeutic: A critical review. J Inflamm (Lond).
13:352016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zubrod CG, Schneiderman M, Frei E III,
Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones R Jr,
Jonsson U, et al: Appraisal of methods for the study of
chemotherapy in man: Comparative therapeutic trial of nitrogen
mustard and thiophosphoramide. J Chronic Dis. 11:7–33. 1960.
View Article : Google Scholar
|
|
10
|
Prostate Cancer: Diagnosis and Management.
NICE Guideline. Published:. 9–May;2019.Available from:. www.nice.org.uk/guidance/ng131December
19–2021
|
|
11
|
Peng H and Luo X: Prognostic significance
of elevated pretreatment systemic inflammatory markers for patients
with prostate cancer: A meta-analysis. Cancer Cell Int. 19:702019.
View Article : Google Scholar
|
|
12
|
Wang J, Zhou X, He Y, Chen X, Liu N, Ding
Z and Li J: Prognostic role of platelet to lymphocyte ratio in
prostate cancer. A meta-analysis. Medicine (Baltimore).
97:e125042018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Caglayan V, Onen E, Avci S, Sambel M,
Kilic M, Oner S, Aydos MM and Yıldız HE: Lymphocyte-to-monocyte
ratio is a valuable marker to predict prostate cancer in patients
with prostate specific antigen between 4 and 10 ng/dl. Arch Ital
Urol Androl. 90:270–275. 2019. View Article : Google Scholar
|
|
14
|
Zhou ZH, Liu F, Wang WJ, Liu X, Sun LJ,
Zhu Y, Ye DW and Zhang GM: Development and validation of a nomogram
including lymphocyte-to-monocyte ratio for initial prostate biopsy:
A double-center retrospective study. Asian J Androl. 23:41–46.
2021. View Article : Google Scholar
|
